CD274 and cancer: With the successes of immune checkpoint inhibitors for advanced cancers, treatments targeting programmed death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are now being evaluated in earlier stages of cancer, and a standardized system for assessing therapeutic benefit is an unmet need.